Your browser is no longer supported. Please, upgrade your browser.
Settings
AXGN [NASD]
AxoGen, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own4.20% Shs Outstand41.08M Perf Week-4.69%
Market Cap567.14M Forward P/E- EPS next Y-0.27 Insider Trans-2.54% Shs Float39.55M Perf Month-14.50%
Income-22.00M PEG- EPS next Q-0.13 Inst Own81.60% Short Float2.39% Perf Quarter-29.94%
Sales130.50M P/S4.35 EPS this Y19.90% Inst Trans0.03% Short Ratio6.78 Perf Half Y-23.48%
Book/sh2.89 P/B4.71 EPS next Y38.10% ROA-11.00% Target Price- Perf Year-1.30%
Cash/sh2.40 P/C5.68 EPS next 5Y- ROE-18.20% 52W Range11.54 - 23.94 Perf YTD-23.91%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-14.90% 52W High-43.11% Beta0.75
Dividend %- Quick Ratio5.90 Sales past 5Y32.70% Gross Margin80.00% 52W Low18.02% ATR0.72
Employees346 Current Ratio6.60 Sales Q/Q52.00% Oper. Margin-15.20% RSI (14)29.65 Volatility4.59% 4.69%
OptionableYes Debt/Eq0.39 EPS Q/Q5.50% Profit Margin-16.90% Rel Volume0.85 Prev Close13.70
ShortableYes LT Debt/Eq0.39 EarningsNov 03 AMC Payout- Avg Volume139.39K Price13.62
Recom1.90 SMA20-11.77% SMA50-15.57% SMA200-28.51% Volume117,985 Change-0.58%
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Mar-02-18Reiterated Lake Street Buy $26 → $38
Jan-05-18Resumed Cantor Fitzgerald Overweight
Nov-30-17Initiated Jefferies Buy $35
Nov-21-17Reiterated Lake Street Buy $22 → $26
Jul-31-17Initiated Leerink Partners Outperform $22
Jun-30-17Initiated Cantor Fitzgerald Overweight $18
Mar-06-17Initiated ROTH Capital Buy $14.50
Nov-22-16Upgrade Lake Street Hold → Buy $9 → $11
Nov-07-16Reiterated Wedbush Outperform $10 → $12
Nov-03-16Downgrade Lake Street Buy → Hold $9
Aug-04-16Reiterated Wedbush Outperform $9 → $10
May-14-14Initiated Dawson James Buy $5
Oct-31-13Reiterated Ladenburg Thalmann Buy $4.50 → $5.75
Oct-13-21 07:00AM  
Sep-22-21 07:00AM  
Sep-01-21 07:00AM  
Aug-18-21 06:35AM  
Aug-05-21 04:30AM  
Aug-04-21 05:55PM  
04:01PM  
Jul-28-21 03:03PM  
Jul-22-21 07:00AM  
Jul-19-21 04:01PM  
Jul-14-21 07:00AM  
Jun-19-21 03:24AM  
May-18-21 08:43AM  
07:00AM  
May-07-21 08:56AM  
May-06-21 07:00AM  
12:31AM  
May-05-21 05:15PM  
04:00PM  
02:45PM  
Apr-28-21 12:34PM  
Apr-20-21 02:06AM  
Apr-14-21 07:00AM  
Mar-01-21 04:01PM  
Feb-22-21 04:01PM  
02:30PM  
Feb-19-21 10:16AM  
Feb-18-21 11:47PM  
07:00AM  
Feb-04-21 07:00AM  
Feb-01-21 07:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Jan-04-21 11:22PM  
Dec-23-20 07:00AM  
Dec-15-20 10:17PM  
Nov-06-20 05:38AM  
Nov-04-20 07:00AM  
Oct-30-20 02:31PM  
Oct-29-20 06:55PM  
04:01PM  
02:45PM  
Oct-28-20 10:15AM  
Oct-08-20 07:00AM  
Sep-30-20 04:01PM  
Sep-25-20 07:00AM  
Sep-24-20 07:00AM  
Aug-31-20 07:00AM  
Aug-07-20 09:48AM  
Aug-05-20 07:45PM  
04:01PM  
Jul-29-20 12:33PM  
07:00AM  
Jul-22-20 07:00AM  
Jul-15-20 07:00AM  
Jul-08-20 06:41PM  
Jul-01-20 07:00AM  
Jun-23-20 09:46AM  
Jun-01-20 07:00AM  
May-20-20 07:00AM  
May-07-20 12:00PM  
May-06-20 04:01PM  
Apr-29-20 12:34PM  
Apr-23-20 07:00AM  
Apr-15-20 07:00AM  
Apr-12-20 09:21AM  
Mar-06-20 07:05AM  
Mar-02-20 07:00AM  
Feb-27-20 07:20AM  
Feb-24-20 04:01PM  
Feb-23-20 06:38PM  
Feb-05-20 07:00AM  
Feb-03-20 07:00AM  
05:55AM  
Jan-13-20 07:00AM  
Jan-08-20 07:00AM  
Jan-02-20 04:01PM  
07:00AM  
Dec-19-19 06:47AM  
Dec-18-19 07:00AM  
Dec-13-19 11:03AM  
Dec-04-19 07:00AM  
Nov-22-19 12:19PM  
Nov-21-19 07:00AM  
Nov-11-19 07:00AM  
Nov-09-19 07:02PM  
Nov-06-19 06:35PM  
04:04PM  
Nov-04-19 06:12AM  
Oct-30-19 10:34AM  
Oct-23-19 07:00AM  
Oct-03-19 01:40PM  
Sep-20-19 10:38AM  
Sep-19-19 07:00AM  
Sep-11-19 08:00PM  
Sep-05-19 12:38AM  
Aug-27-19 07:00AM  
Aug-18-19 05:59PM  
Aug-14-19 09:02PM  
01:55PM  
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zaderej Karen L.CEOAug 13Option Exercise3.6746,500170,655868,772Aug 16 04:10 PM
Zaderej Karen L.CEOAug 12Option Exercise5.098,25442,013822,272Aug 16 04:10 PM
Zaderej Karen L.CEOAug 10Option Exercise5.0975,000381,750855,018Aug 10 04:52 PM
Zaderej Karen L.CEOAug 06Sale18.4741,000757,194814,018Aug 10 04:52 PM
Donovan Michael PatrickVP OperationsJul 21Sale20.041,93538,77740,839Jul 23 04:06 PM
Freitag Gregory GeneDirectorJun 17Option Exercise19.179,250177,323364,556Jun 21 04:17 PM
MARTINEZ MARIA D.Chief Human Resources OfficerJun 04Sale18.862,65250,0172,932Jun 08 04:25 PM
Gold Mark StephenDirectorJun 01Option Exercise0.006,1730302,439Jun 03 05:15 PM
Wendell Amy McBrideDirectorJun 01Option Exercise0.006,173032,097Jun 03 05:14 PM
NEELS GUIDO JDirectorJun 01Option Exercise0.006,173048,764Jun 03 05:12 PM
Blackford Quentin S.DirectorJun 01Option Exercise0.006,173024,299Jun 03 05:13 PM
Levine Alan MDirectorJun 01Option Exercise0.006,17308,764Jun 03 05:11 PM
Freitag Gregory GeneDirectorMay 26Option Exercise6.72102,954692,001331,306May 28 04:05 PM
NEELS GUIDO JDirectorMay 19Option Exercise4.2840,000171,35042,591May 21 04:21 PM
DeVinney Erick WayneVP of Clin. & Trans. SciencesApr 28Option Exercise2.8610,00028,60078,082Apr 30 04:10 PM
Zaderej Karen L.CEOApr 16Option Exercise5.09100,000509,000765,912Apr 20 04:09 PM
Zaderej Karen L.CEOMar 25Option Exercise3.6734,500126,615665,912Mar 29 04:17 PM
Freitag Gregory GeneDirectorFeb 25Sale22.0624,000529,440228,352Mar 01 04:08 PM
Donovan Michael PatrickVP OperationsFeb 18Sale19.151,80834,62340,839Feb 19 04:12 PM
Donovan Michael PatrickVP OperationsFeb 05Option Exercise5.1420,000102,80046,029Feb 09 07:12 PM
Zaderej Karen L.CEOJan 08Sale20.0065,0001,300,000609,099Jan 12 04:08 PM
Donovan Michael PatrickVP OperationsDec 30Sale17.481,73330,29326,029Dec 31 04:06 PM
DeVinney Erick WayneVP, Clinical&Translational ScDec 29Sale17.813716,60863,240Dec 30 05:33 PM
Donovan Michael PatrickVP OperationsDec 29Sale17.8156710,09827,762Dec 30 04:09 PM
Freitag Gregory GeneDirectorDec 29Sale17.8191616,314248,345Dec 30 12:53 PM
Scopelianos AngeloVP Research & DevelopmentDec 29Sale17.8156710,0985,529Dec 30 11:55 AM
MARIANI PETER JChief Financial OfficerDec 29Sale17.811,29323,02810,376Dec 30 11:56 AM
Zaderej Karen L.CEODec 29Sale17.813,50062,335674,099Dec 30 11:53 AM
MARTINEZ MARIA D.Chief Human Resources OfficerDec 29Sale17.8156710,0984,665Dec 30 11:51 AM
Friedman Mark LouisVP,Regulatory & QualityDec 29Sale17.8156710,09811,124Dec 30 11:52 AM
Billet IsabelleChief Strategy and BD OfficerDec 29Sale17.8164911,5599,496Dec 30 11:51 AM
Zaderej Karen L.CEODec 23Option Exercise4.8119,37593,194666,094Dec 28 09:26 AM
Donovan Michael PatrickVP OperationsDec 22Sale17.192794,79626,029Dec 23 02:32 PM
DeVinney Erick WayneVP, Clinical&Translational ScDec 21Sale16.421472,41462,111Dec 22 03:22 PM
Freitag Gregory GeneDirectorDec 21Sale16.423796,223245,076Dec 22 03:15 PM
Donovan Michael PatrickVP OperationsDec 21Sale16.42961,57626,308Dec 22 01:55 PM
MARIANI PETER JChief Financial OfficerDec 21Sale16.424817,8986,419Dec 22 12:54 PM
Friedman Mark LouisVP,Regulatory & QualityDec 21Sale16.42961,5768,893Dec 22 11:38 AM
Zaderej Karen L.CEODec 21Sale16.421,27520,936646,719Dec 22 05:32 PM
DeVinney Erick WayneVP, Clinical&Translational ScDec 15Option Exercise4.8115,00072,15066,056Dec 17 04:41 PM
Friedman Mark LouisVP,Regulatory & QualityDec 03Option Exercise3.863,81214,7038,614Dec 07 02:39 PM
Donovan Michael PatrickVP OperationsNov 09Sale15.0017,617264,25526,029Nov 12 10:14 AM
Zaderej Karen L.CEONov 09Sale14.5314,000203,420644,869Nov 10 09:56 AM
MARIANI PETER JChief Financial OfficerOct 30Option Exercise5.0460,000302,40080,683Nov 03 05:11 PM
MARIANI PETER JChief Financial OfficerOct 30Sale12.4175,683939,3535,000Nov 03 05:11 PM